
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
Entrapment of miconazole nitrate in liposomes was achieved after studying the effect of various process and formulation variables.
about 24 years ago
Contract Servicesabout 24 years ago
Major Changes Ahead for FDAabout 24 years ago
Residual Solvent Analysis in Pharmaceuticals





